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Evidence is presented to show that mice treated with 
various regimens of 8-methoxypsoralen followed by ex-
posure to long-wave ultraviolet light (PUV A) are ren-
dered tumor-susceptible when challenged with short-
wave ultraviolet light (UVB) induced regressor tumors. 
These same tumors are readily rejected when implanted 
into normal syngeneic animals. Similar observations 
have been made in mice treated with subcarcinogenic 
doses of UVB, where it was shown that the tumor-sus-
ceptible state is mediated by suppressor T lymphocytes. 
These suppressor T -cells may be generated in response 
to antigens expressed by UVB damaged skin cells. It is 
now known that suppressor T-cells generated in mice 
treated with UVB are la-positive and have specificities 
for cross-reacting tumor antigens shared by all UVB-
induced tumors, which have been tested to date. Our 
data suggest that, like UVB treated mice, treatment of 
mice with PUV A results in tumor-susceptibility me-
diated through the generation of la + suppressor cells. 
Since PUV A treatments appear to generate a suppressor 
cell response in mice, a possible mechanism by which 
these treatments act to manage autoimmune type skin 
diseases, such as vitiligo, is discussed. 
Chronic exposure to short-wave ultraviolet light (280-320 
nm, UVB) has been shown to be carcinogenic in mice [1-3] and 
is suggested as such in man [1,4,5]. The tumors which arise in 
the mouse are of 2 immunologic types [6]. Tumors termed 
"progressors" grow readily when transplanted into normal syn-
geneic hosts. On the other hand, the majority of tumors induced 
by UVB are highly immunogenic, and are rejected when im-
planted into secondary normal syngeneic animals. Because 
these tumors are rejected by a secondary host, they have been 
termed "regressor" tumors. Regressor tumors are only capable 
of growth in the primary host or when transplanted into im-
munologically compromised secondary syngeneic hosts [6-8]. 
Recently it has been shown that subcarcinogenic exposures to 
UVB will render syngeneic mice susceptible to the growth of a 
UV-regressor tumor challenge [7-9]. It is now known that this 
tumor-susceptible state is mediated by suppressor T lympho-
cytes as evidenced by the ability to adoptively transfer suscep-
tibility to normal mice using splenic T -cells from the short term 
UVB irradiated mice [10]. The suppressive state in UVB treated 
mice can be abrogated with repeated injections of small doses 
of antisera directed toward the Ia subregion of the mouse H-2. 
In addition, the ability to transfer suppression with splenic T-
cells has also been shown to be dependent upon an Ia + cell 
[11]. 
Like the effect of chronic UVB exposure, prolonged treat-
Manuscript received September 21, 1978; accepted for publication 
December 21, 1978. 
This investigation was supported by Grant Number CA-22126-02, 
awarded by the National Cancer Institute, DHEW. 
Reprint requests to: Dr. R. A. Daynes, D epartment of Pathology, 
University of Utah Medical Center, Salt Lake City, Utah 84132. 
Abbreviation: . 
8-MOP: 8-methoxypsoralen 
ments with 8-methoxypsoralen (8-MOP) followed by exposure 
to long-wave ultraviolet light (320-400 nm, UV A) (PUV A) has 
been found to be carcinogenic in mice [12-15]. Unlike the 
carcinogenic effect of UVB, there is essentially no suggestive 
evidence to show that PUV A is carcinogenic in man, at best it 
has been implied in a single case study that short term PUV A 
treatment in man may act as a co-carcinogen [16]. Since chronic 
exposures to either UVB or PUV A have been found to be 
carcinogenic in mice, coupled with the fact that PUV A is widely 
used in the clinical treatment of such diseases as vitiligo [17-
18] and psoriasis [19-21], we felt an evaluation should be made 
to correlate between the effects of PUV A and UVB at subcar-
cinogenic doses in regard to UV-tumor immunology. 
The following study was undertaken to determine if, like 
UVB, acute treatments with PUV A would render a host tumor-
susceptible to growth of a UV -regressor tumor challenge. In 
addition, we attempted to determine that if PUV A does render 
a host tumor-susceptible, whether the suppressed immunologic 
state is mediated by suppressor cells as it appears to be following 
acute UVB exposure. 
MATERIALS AND METHODS 
Animals 
Normal 4- to 6-week-old C3Hf/HeN female mice were obtained from 
Charles River Breeding Laboratories, Wilmington, Mass. All mice were 
housed at a density of 4 to 6 animals per standard 7 x 11 inch cage and 
maintained on Waynes Lab Blox and acidified water ad libitum. Age 
matched mice were 8 to 10 weeks old at the onset of all experiments. 
8-Methoxypsoralen and Long Wave Ultraviolet Radiation 
Oxsoralen (1.0% 8-MOP, Paul B. Elder Co., Bryan, Ohio) was diluted 
in a solution of 30% acetone and 70% ethyl alcohol to 0.1% 8-MOP and 
applied to the shaved dorsal surface of each animal with a 50 Jll Lancer 
repeating pipet (Sherwood Medical Industries, St. Louis, MO.) . Thirty 
minutes following the 8-MOP application, animals received various 
lengths of exposure to long-wave ultraviolet light, as indicated in the 
Results section. The light source consisted of a bank of 6 General 
Electric F40BL lamps. The light emitted was principally between 340 
to 380 nm wave lengths with a total energy output of 4.50 x 10" ergs/ 
cm2/ sec. Animals were treated 5 times per week for 6 to 8 weeks prior 
to tumor challenge. Animals which served as controls in various exper-
iments received either 8-MOP alone or long wave UV alone, at the 
same dosages and durat ions as described above. 
Short -Wave Ultraviolet Radiation 
Short-wave UV light was administered to the animals (shaved of 
dorsal hair) using banks of six FS-40 Westinghouse fluorescent sun 
lamps emitting principally (>60%) between 280 and 320 nm wave 
lengths with a total energy output of 1.79 x lO'J ergs!cm2!sec. Animals 
were treated 30 min per day, 5 days per week for 6 to 9 weeks prior to 
tumor challenge. 
Tumor 
The induct ion of primary UV-induced tumors has been previously 
described [7]. The UV tumor RD 87 (a spindle cell fibrosarcoma) used 
in these experiments has been designated to be a "regressor tumor" 
because it is rejected when transplanted into normal syngeneic mice. 
However, when this tumor is t ransplanted into UV treated syngeneic 
mice it will grow progressively. All challenges were made by subcuta-
neous trocar implants of tumor fragments (1 mm:!) into the ventral side 
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of the mouse. Tumor growth was followed by making external decimeter 
measurements with calipers. 
Antiserum 
Anti-Iak was prepared by weekly immunization of A.TH mice with 
A.TL lymphocytes (15-30 X 10(; cells/injection). The animals were bled 
7 days after the 6th immunization from the retro-orbital sinus and 
weekly thereafter. Booster immunizations were given the day following 
each bleeding. Each bleeding was pooled and the serum evaluated for 
cytotoxicity on C3Hf spleen cells, which titered at 1:500 (approximately 
50% cytotoxicity) in a microcytotoxicity assay. Beginning the day of 
tumor challenge, each mouse received 80 ,.u of antiserum by i.v. injec-
tion, given as 3 protracted doses, each week (20 J.d , Monday; 20 Ill, 
Wednesday; and 40 Ill , Friday). Treatment continued throughout the 
duration of the experiment. This antiserum has been shown to interfere 
with suppressor T-cell function while leaving effector T-cell fun ction 
intact in mice treated with subcarcinogenic doses of UVB [ll]. 
RESULTS 
Since UV -induced regressor tumors have been shown to grow 
progressively in syngeneic mice treated with subcarcinogenic 
doses of UVB [7-9], the following experiments were performed 
to determine whether PUV A, when administered at subcarcin-
ogenic doses, would also be capable of rendering the animals 
susceptible to growth of a UV-regressor tumor challenge. Two 
experiments, consisting of groups of mice which received var-
ious 8-MOP and UV A treatments prior to challenge with the 
UV-regressor tumor RD 87, were run. In the fIrst experiment 
mice were treated with 8-MOP, rested 60 min, followed by 45 
min of UV A exposure. In the second experiment the UV A 
exposure was extended to 60 min. Control groups of mice 
received either 8-MOP treatments alone or UV A alone at the 
same doses and durations as animals treated in the PUV A 
treatment group. A group of normal mice and a group of UVB 
treated mice were also included. The results of these 2 experi-
ments are presented in the Table. The data is expressed as the 
number of animals which progressively grew RD 87. Both 
experiments demonstrated that mice treated with PUV A were 
rendered tumor-susceptible to the same extent as animals 
treated with UVB. Like normal animals, treatment with either 
8-MOP or UVA alone resulted in rejection of the UV-regressor 
tumor challenge. It, therefore, appears that the combined effect 
of 8-MOP and UVA is capable of causing a modifIcation in the 
host defense mechanism which alters its capability to reject a 
UV-regressor tumor. 
An experiment was then performed to determine if the rate 
of tumor growth in PUV A-treated animals was the same as in 
UVB tumor-susceptible animals. Previous studies have shown 
that optimal growth for an average UV-regressor tumor is 
achieved in mice which have been exposed to UVB for approx-
imately 6 weeks, at 30 min/ day, 5 times/week, or a total of 
approximately 65.2 Joules/animal under our experimental con-
Host susceptibility to a UV-regressor tumor challenge in mice 
treated with a combination of 8-MOP and UVA 
Group Animal 
Number of TBA/mice challenged" 
treatments Experiment 1 h Experiment 2" 
1 PUVA" 1l/ 12 (92) 10/10 (100) 
2 UVA only 2/12 (17) 0/ 10 (0) 
3 8-MOP only 0/12 (0) 0/10 (0) 
4 Normals 1/6 (17) 0/5 (0) 
5 UVB' 6/6 (100) 5/5 (100) 
" Numbers and (percent) of tumor bearing animals implanted with 
UV-tumor RD 87. 
" Long-wave ultraviolet exposure of 45 min following 8-MOP treat-
ment. 
e Long-wave ultraviolet exposure of 60 min following 8-MOP treat-
ment. 
"Treatments made 5 days/week for 7 weeks, with 50 III 8-MOP 
administered 1 hr prior to UV A exposure. 
e Six weeks of UVB at 30 min exposures/day (5 days/week). 
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FIG 1. Comparison of growth rates for RD 87 tumor implants in 
mice rendered tumor-susceptible by either UVB or PUV A. UV A 
treated (_), normal controls (0), PUVA treated (0), and UVB treated 
(e). Tumor size is the product of 2 perpendicular diameters measured 
on each tumor and is expressed as the mean for all the animals in a 
particular group. Each group consisted of 6 to 8 animals. 
ditions [7]. In order to make growth rate comparisons, 4 treat-
ment groups were challenged with 1 mm:J RD 87 tumor frag-
ments and caliper measurements taken on each tumor period-
ically for the duration of the experiment. The growth rates were 
determined by calculating the product of 2 perpendicular di-
ameters on each tumor and taking the average of all the animals 
challenged in a particular group. The points presented in Fig 1 
are comparisons of the average tumor sizes between groups 
with respect to time. From this fIgure it is clear that mice 
treated for 6 weeks with PUV A (50 ,.u 0.1% psoralen, with 30 
minute rest, followed by 90 min of UV A 5 times/week, a total 
of approximately 273.3 Joules/animal) are rendered susceptible 
to UV -regressor tumor growth at a rate which is comparable to 
that seen in mice receiving 6 weeks of UVB as described earlier. 
Tumor challenge of normal mice as well as mice treated with 
UV A only (for the same duration as PUV A treated animals) 
resulted in rejection of tumor as expected. When the data is 
tested by analysis of covariance, no statistical difference is seen 
between the UVB or PUV A groups, the same statement holds 
when comparing the UV A only and normal groups. However, 
the growth rates between UVB and PUV A compared to normal 
and UV A groups is signifIcantly different at p s: .Ol. 
In a separate experiment an attempt was made to determine 
if the suppressive state established in mice treated with subcar-
cinogenic doses of PUV A was mediated or influenced by an Ia-
positive cell. Animals treated for 8 weeks with PUV A (50 J.Ll 
psoralen, with 30 minutes rest, followed by 90 min UV A, 5 
times/week) received injections of A.TH anti A.TL (anti-Iak ) 
serum beginning the day of tumor challenge and continuing for 
the duration of the experiment as described in the Materials 
and Methods section. Such antisera have specifIcities capable 
of abrogating the effectiveness of Ia+ suppressor cells which 
have been shown to function in other tumor systems [22,23]. It 
can be concluded from the tumor growth rates presented in Fig 
2 that the tumor-susceptible state induced in mice treated with 
PUV A is mediated or influenced by an Ia + suppressor celi, since 
the treatment of PUVA mice with anti-Iak serum abrogates 
their ability to grow tumor as indicated by a signifIcant decrease 
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FIG 2. AbrogatiOll of PUV A induced tumor-susceptibility in animals 
treated with anti-la' serum at the time of tumor challenge. PUVA 
treated (0), PUVA plus anti-la' serum treatrrients (_), and normal 
controls (0). Tumor size is the product of 2 perpendicular diameters 
measured on each tumor and is expressed as the mean for all the 
animals in a particular group. Each group consisted of 5 animals. 
in tumor growth rate compared to that observed in the PUV A-
treated group. These results are similar to those obtained using 
animals made susceptible to tumor challenge with UVB, where 
it was shown that treatments with anti-Iak serum abrogates the 
suppressive state [11). 
DISCUSSION 
Mice can be rendered susceptible to tumor growth, when 
assayed by challenge with a UV -regressor tumor, if prior to 
tumor implantation the animals are exposed to sub carcinogenic 
doses of short-wave ultraviolet light [7-9). The suppressed 
immunologic state, at least in part, is mediated by suppressor 
T lymphocytes with antigen specificities directed toward cross-
reacting tumor antigens expressed by individual UV-induced 
tumors [24). These suppressor T-cells, which have specificities 
for the cross-reacting tumor antigens, may be generated as part 
of the immunologic response elicited toward antigens expressed 
by UVB damaged skin cells [25). The induction of suppressor 
T-cells with specificities for antigens shared by UVB damaged 
skin cells and UVB-induced tumors, may explain why such 
tumors, which are highly immunogenic, are allowed to grow in 
an otherwise immllnocompetent host [26]. From the evidence 
presented it is clear that short-term treatment of mice with a 
combination of 8-MOP and UV A is also capable ·of rendering a 
treated host tumor-susceptible. 
In adoptive transfer experiments with spleen cells from UVB-
treated mice, it was noted that a titration effect was seen as far 
as the ability to transform a normal animal into a tumor-
susceptible host [27]. To date we have been unable to adop-
tively transfer tumor-susceptibility with spleen cells from 
PUV A treated animals. This does not negate the possibility 
that tumor-susceptibility in PUV A treated animals is mediated 
by a suppressor T-cell mechanism since we may be dealing with 
a titration effect where enough PUV A spleen cells are not being 
passed to render a normal host tumor-susceptible. The evidence 
that anti-Iak serum abrogates the tumor-susceptible state is at 
least suggestive that Ia+ cells are involved. Although our data 
suggest an Ia+ cellular mechanism, further attempts to transfer 
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susceptibility with PUV A spleen cells must be pursued before 
a conclusive statement can be made on this point. 
The treatment of vitiligo and psoriasis with PUV A has been 
proven beneficial in many cases [17- 21). Recently it has been 
suggested that vitiligo might be the manifestation of an autoim-
mune disease [28,29). Because little is known about the mech-
anism by which photosensitizing agents, such as 8-MOP, act to 
enhance repigmentation of the skin in vitiligo patients, it could 
be suggested that treatments with these agents induce or aug-
ment the formation of suppressor T -cells with specificity for the 
same antigens expressed by the skin cells to which the autoim-
mune response is directed. It could then be argued that the 
suppressor T -cells are capable of repressing the vitiligo episode 
via a cellular immune regulatory mechanism. 
The same phenomenon which may act to regulate the im-
mune response in vitiligo, i.e., the formation of suppressor T-
cells, may be similar in mechanism to that which results in an 
increased tumor incidence with age. This was eluded to in an 
investigation in which normal, old-aged mice were shown to be 
susceptible to tumor growth when challenged with a UV-re-
gressor tumor [30). Thus any mechanism capable of enhancing 
suppressor cell formation, whether it be the aging process or 
prolonged exposure to UVB or PUV A, could very well increase 
the host's chances of developing a cancer through a suppressive 
mechanism which may alter the effectiveness of the tumor 
immune surveillance system. 
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Announcements 
It is proposed to hold a Symposium on the Physiology and Pathophysiology of the Skin in Iceland 
during the early part of May 1980. The contributors to the volumes already published on this subject by 
Academic Press of London and New York will give lectures and hold seminars and discussion groups on 
their special subjects. Those wishing to attend the meeting who have themselves been involved in research 
in the relevant subject are invited to submit short papers. 
The Symposium will be held at the Hotel Loftleidir, Reykjavik, Iceland. The estimated cost for 
participants from New York or London is £360 (720 UB. dollars), which will include conference fees, full 
board for 8 days for those from the U.K., and for 7 days for those from the U.S.A. There will be a banquet 
on one of the evenings. The cost includes return air fare New York - Reykjavik - New York for those 
attending from the States and the return fare London - Reykjavik - London for those attending from 
Europe. 
The meeting is intended for dermatologists in training but biologists and other scientists interested in 
the function and disorders of the skin are very welcome. 
Anyone interested in attending should write to Dr. A. Jarrett, Department of Dermatology, University 
College Hospital Medical School, London WC1E 6JJ for registration forms, which should be returned by 
July 20th, 1979. ' 
